Ketamine: A Promising Rapid-Acting Antidepressant
Wilkinson S, Ostroff R, Katz R, Krystal J. Ketamine: A Promising Rapid-Acting Antidepressant. 2017, 223-239. DOI: 10.1007/978-981-10-6577-4_16.Peer-Reviewed Original ResearchMood disordersDeficiency hypothesisInitiation of therapyRapid antidepressant effectsRapid acting antidepressantsEvidence-based treatmentsLong-term riskMood disorders researchRelapse prevention strategiesEfficient therapeutic targetMechanism of actionOral antidepressantsAntidepressant effectsGlutamatergic receptorsGlutamatergic systemNovel antidepressantsSingle doseClinical trialsKetamine exposureRelated symptomsLong-term effectsPsychiatric disordersPrevention strategiesTherapeutic targetDrug AdministrationKetamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression
Esterlis I, DellaGioia N, Pietrzak RH, Matuskey D, Nabulsi N, Abdallah CG, Yang J, Pittenger C, Sanacora G, Krystal JH, Parsey RV, Carson RE, DeLorenzo C. Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression. Molecular Psychiatry 2017, 23: 824-832. PMID: 28397841, PMCID: PMC5636649, DOI: 10.1038/mp.2017.58.Peer-Reviewed Original ResearchConceptsMajor depressive disorderMGluR5 availabilityPositron emission tomographyKetamine administrationControl groupAspartate glutamate receptor antagonistIntravenous ketamine administrationKetamine-induced reductionMetabotropic glutamatergic receptorsRapid antidepressant effectsGlutamate receptor antagonistsKetamine-induced changesEffects of ketaminePET imaging studiesMechanism of actionGlutamate surgeAntidepressant effectsAntidepressant efficacyAntidepressant responseGlutamatergic receptorsControl subjectsReceptor antagonistHealthy controlsDepressive disorderSustained decrease